enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
0.3700
+0.0360 (10.78%)
Jan 14, 2026, 3:33 PM EST - Market open
enVVeno Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
7.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NVNO News
- 7 weeks ago - enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment - Accesswire
- 2 months ago - enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve - Accesswire
- 2 months ago - enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 3 months ago - enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment - Accesswire
- 4 months ago - enVVeno Medical Updates Regulatory Status of VenoValve(R) - Accesswire
- 5 months ago - enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) - Accesswire
- 5 months ago - enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Accesswire
- 5 months ago - Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency - Accesswire